News Article | May 1, 2017
Em seu quarto ano, o Prêmio para o Desenvolvimento da Aférese da Terumo BCT é parte do compromisso de longo prazo de apoiar aqueles que aprimoram os cuidados ao paciente no uso da aférese terapêutica e coleções de células. A cada ano, o ganhador é escolhido por uma comissão externa global composta de importantes líderes de opinião. Sua decisão baseou-se nas considerações dos planos do AUH para o uso do prêmio, sua história de demonstração de liderança educacional e seu impacto para a comunidade. A comissão do subsídio da Terumo BCT 2016 foi composta por: A cada ano, o Prêmio para o Desenvolvimento da Aférese apresenta um foco diferente. Em 2016, concentrou-se na solução das dificuldades do acesso venoso. "Selecionar e garantir a abordagem apropriada ao acesso vascular é um desafio; aprimorar o acesso periférico pode levar à melhoria da experiência clínica e do paciente. É um privilégio homenagear as iniciativas de médicos, profissionais da saúde e operadores que continuam a aprimorar a experiência e os resultados de pacientes ao redor do mundo", disse Monte Smith, vice-presidente, sistemas terapêuticos globais da Terumo BCT. Pela primeira vez na história do Prêmio para o Desenvolvimento da Aférese, a Terumo BCT incluiu um defensor dos pacientes na comissão de avaliação. Ed Harris atua como diretor executivo e fellow de pesquisas no departamento de Imunologia e Microbiologia Médica da University of Wisconsin–Madison. Harris foi um paciente em mais de 365 procedimentos de aférese terapêutica, todos executados com acesso venoso periférico. Sobre a Terumo BCT A Terumo BCT, líder global em tecnologias celulares, aférese terapêutica e componentes sanguíneos, é a única empresa com a combinação exclusiva de coleções por aférese, processamento de sangue total manual e automatizado, e tecnologias de redução patogênica. Acreditamos que o sangue pode fazer ainda mais do que faz atualmente para pacientes. A convicção desse potencial nos inspira à inovação e fortalece nossa colaboração com os clientes.
News Article | November 10, 2016
The global cell isolation market is expected to reach USD 7.89 billion by 2021, at a CAGR of 17.2% driven by increasing government funding for cell based research and expanding biotechnology and biopharmaceutical industries while human cells segment is projected to witness the largest growth rate in cell separation market. Complete report on global cell isolation/ cell separation market spread across 172 pages, profiling 10 companies and supported with 124 tables and 46 figures is now available at http://www.rnrmarketresearch.com/cell-isolationcell-separation-market-by-product-reagent-media-bead-centrifuge-cell-type-human-stem-cell-animal-technique-filtration-surface-marker-application-research-ivd-by-end-market-report.html. On the basis of product, the cell isolation market is segmented into consumables and instruments. In 2016, the consumables segment is expected to account for the largest share of the global cell separation. Growth in this segment can primarily be attributed to the increasing investments by companies to develop advanced products and rising government initiatives for enhancing cell-based research. On the basis of technique, the cell isolation market is segmented into centrifugation-based cell isolation, surface marker-based cell separation, and filtration-based cell separation. In 2016, the centrifugation-based cell isolation segment is expected to account for the largest share of the global cell isolation market primarily due to the wide usage of this technique among end users. This system is used on a large scale by biotechnology and biopharmaceutical companies as well as on a small scale by clinical research organizations and academia for manufacturing vaccines, enzymes, and antibodies. On the basis of cell type, the cell isolation market is segmented into human cells and animal cells. The human cells segment is expected to account for the largest share of the global cell isolation market during the forecast period. Technological advancements in treatments and increasing incidence of skin diseases are the key factors propelling the growth of the cell separation market. On the basis of application, the cell isolation market is segmented into bio molecule isolation, stem cell research, cancer research, in vitro diagnostics, and therapeutics. Increasing company investments to develop new biopharmaceutical products is a major factor contributing to the growth of this market segment. North America is the largest regional segment in the cell separation market, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Factors such as increasing interest in emerging markets, government support, and high prevalence of diseases are driving the growth of this market. Key players in the cell isolation/cell separation market include by Beckman Coulter (U.S.), BD Biosciences (U.S.), GE Healthcare (U.K.), Merck Millipore (U.S.), Miltenyi Biotec (Germany), pluriSelect (Germany), STEMCELL Technologies Inc. (Canada), Terumo BCT (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and Bio-Rad Laboratories Inc.(U.S.). Order a copy of Cell Isolation/Cell Separation Market by Product (Reagents, Media, Serum, Beads, Centrifuge), Cell Type (Human, Stem, Animal), Technique (Surface marker, Filtration), Application (Cancer, IVD), End User (Hospitals, Biotechnology) - Global Forecast to 2021 research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=213818. Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. On a related note, another research on Cell Expansion Market Global Forecasts to 2021 says, the cell expansion market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Increasing government funding for research, high prevalence of chronic diseases, and growing number of GMP-certified production facilities are the major growth factors. The overall market is expected to reach USD18.76 billion by 2021 from USD 8.34 billion in 2016 at a CAGR of 17.6%. Companies like Beckman Coulter, Inc., Becton, Dickinson and Company, Corning, Inc., GE Healthcare, Lonza, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Inc., Terumo BCT, Inc. and Thermo Fisher Scientific, Inc. have been profiled in this 189 pages research report available at http://www.rnrmarketresearch.com/cell-expansion-market-by-product-reagent-media-serum-bioreactors-centrifuge-cell-type-human-animal-application-stem-cell-research-regenerative-medicine-clinical-diagnostics-end-user-h-market-report.html. Explore more reports on Life Sciences market at http://www.rnrmarketresearch.com/reports/life-sciences. RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.
News Article | November 18, 2016
Platelets are small cells in the blood responsible for clotting of the damaged blood vessels. Blood vessels are responsible for carrying blood through the body. In an event when blood vessels are damaged, platelets bind together at the damaged surface and clot the area, preventing blood loss. The process of clotting begins after the damaged vessels send signals which are received by the platelets. The platelets travel to the damaged area and reshape themselves to form a mesh and get attached to the damaged surface and prevent bleeding. For proper functioning of the clotting process an appropriate number of platelets are required in the human body. In some cases the platelets stop functioning properly and lose their ability to bind to the damaged site and stop bleeding. These disorders may be hereditary or acquired and increase the risk of fatality in the patient. These disorders include inefficacy in the process of platelet adhesion, platelet aggregation, platelet secretion, procoagulant activity and abnormalities in formation of new platelets, therefore it is necessary for the check the functioning of the platelets. The platelet function tests are designed to test the problems associated with production and functioning of the platelets in the blood. With the increasing number of platelet disorders the demand for the platelet function test is increasing rapidly. Increasing incidence rate of disorders like thrombocythemia (abnormal increase in the number of platelets) and thrombocytopenia (decrease in the number of platelets) is expected to boost the demand for platelet function test market during the forecast period. It has been observed that the platelet function disorders are 1.5 times more likely to occur in women and geriatric population, with the increasing global life expectancy rate there is expansion in the patient pool requiring platelet function test, which in turn is expected to drive demand for platelet function test market. Increasing adoption of platelet therapy for cancer patients is also expected to boost the platelet function test market due to increasing number of cancer patients. Some other factors like increasing number of surgical procedures, increasing awareness and development of new technology is expected to boost the platelet function test market. However reduction in the reimbursement rates for the tests and dearth of trained professionals in the emerging economies is expected to decelerate the market growth. The global platelet function test market is segment into following segments: by product type, by end user, by application and by region. Geographically, the platelet function test market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East and Africa (MEA). North America and Western Europe are expected to lead the platelet function test market during the forecast period, mainly due to high adoption rate of platelet function test and high awareness of platelet related disorders. Also the presence of several manufacturers and increasing rate of clinical research is expected to promote platelet function test market growth in this region. APEJ region is expected to witness high market growth followed by North America and Western Europe mainly due to large patient population and development of affordable platelet function tests by the manufacturers owing to low taxation rates. The improving distribution channel and large patient pool in this region is also expected to boost the platelet function test market. Eastern Europe, Japan and Latin America are expected to follow next due to increasing government spending on the healthcare and development of efficient reforms for manufacturers of platelet function test kits and systems. MEA is also expected to witness significant growth in the platelet function test market owing to improving political stability and increasing awareness related to platelet disorders. Some key participants in the platelet function test market are F. Hoffmann-La Roche Ltd, Haemonetics Corporation, Siemens AG, Accriva Diagnostics, Helena Laboratories, Terumo BCT, Inc., Fresenius SE & Co KGaA., and Aggredyne, Inc. Currently companies are focusing on developing more accurate test systems and analyzers along with constant effort to establish distribution channel in the emerging countries.
News Article | November 30, 2016
WiseGuyReports.Com Publish a New Market Research Report On – “Apheresis Equipment Market by Manufacturers,Types,Regions and Applications Research Report Forecast to 2021”. Apheresis is an invasive process that involves the separation of components such as platelets, RBC, plasma, and other components from whole blood. In this procedure, the blood of a donor or a patient is passed through an apheresis machine or a blood cell separator.An apheresis machine is a device which receives blood removed from a patient or donor’s body and separates it into its various components plasma, platelets, white blood cells and red blood cells. Depending on the reason for apheresis, one of these components is isolated and collected by the instrument, while the others are returned to the body. The apheresis equipment spins the blood to separate the required component from other blood components. A selected part of the blood is removed, and the remaining elements are returned to the donor or the patient. It involves the use of devices and disposables along with separation technologies such as centrifugation and membrane filtration. The equipment used in apheresis include manual and automated systems. For more information or any query mail at [email protected] Scope of the Report This report focuses on the Apheresis Equipment in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Manufacturers, this report covers Haemonetics Corporation Fresenius Medical Care Terumo BCT, Inc. Asahi Kasei Medical Co., Ltd. Kawasumi Laboratories Inc. B. Braun Melsungen AG Therakos NIKKISO Macopharma Medica SPA. Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America, Middle East and Africa Market Segment by Applications, can be divided into Plasma Platelets RBC Others Global Apheresis Equipment Market by Manufacturers, Regions, Type and Application, Forecast to 2021 1 Market Overview 1.1 Apheresis Equipment Introduction 1.2 Market Analysis by Type 1.2.1 Membrane Apheresis Equipment 1.2.2 Centrifugation Apheresis Equipment 1.2.3 1.3 Market Analysis by Applications 1.3.1 Plasma 1.3.2 Platelets 1.3.3 RBC 1.4 Market Analysis by Regions 1.4.1 North America (USA, Canada and Mexico) 126.96.36.199 USA 188.8.131.52 Canada 184.108.40.206 Mexico 1.4.2 Europe (Germany, France, UK, Russia and Italy) 220.127.116.11 Germany 18.104.22.168 France 22.214.171.124 UK 126.96.36.199 Russia 188.8.131.52 Italy 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 184.108.40.206 China 220.127.116.11 Japan 18.104.22.168 Korea 22.214.171.124 India 126.96.36.199 Southeast Asia 1.4.4 South America, Middle East and Africa 188.8.131.52 Brazil 184.108.40.206 Egypt 220.127.116.11 Saudi Arabia 18.104.22.168 South Africa 22.214.171.124 Nigeria 1.5 Market Dynamics 1.5.1 Market Opportunities 1.5.2 Market Risk 1.5.3 Market Driving Force 2 Manufacturers Profiles 2.1 Haemonetics Corporation 2.1.1 Business Overview 2.1.2 Apheresis Equipment Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.1.3 Haemonetics Corporation Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.2 Fresenius Medical Care 2.2.1 Business Overview 2.2.2 Apheresis Equipment Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.2.3 Fresenius Medical Care Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.3 Terumo BCT, Inc. 2.3.1 Business Overview 2.3.2 Apheresis Equipment Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.3.3 Terumo BCT, Inc. Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.4 Asahi Kasei Medical Co., Ltd. 2.4.1 Business Overview 2.4.2 Apheresis Equipment Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.4.3 Asahi Kasei Medical Co., Ltd. Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.5 Kawasumi Laboratories Inc. 2.5.1 Business Overview 2.5.2 Apheresis Equipment Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.5.3 Kawasumi Laboratories Inc. Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.6 B. Braun Melsungen AG 2.6.1 Business Overview 2.6.2 Apheresis Equipment Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.6.3 B. Braun Melsungen AG Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.7 Therakos 2.7.1 Business Overview 2.7.2 Apheresis Equipment Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.7.3 Therakos Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.8 NIKKISO 2.8.1 Business Overview 2.8.2 Apheresis Equipment Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.8.3 NIKKISO Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.9 Macopharma 2.9.1 Business Overview 2.9.2 Apheresis Equipment Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.9.3 Macopharma Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 2.10 Medica SPA. 2.10.1 Business Overview 2.10.2 Apheresis Equipment Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.10.3 Medica SPA. Apheresis Equipment Sales, Price, Revenue, Gross Margin and Market Share 3 Global Apheresis Equipment Market Competition, by Manufacturer 3.1 Global Apheresis Equipment Sales and Market Share by Manufacturer 3.2 Global Apheresis Equipment Revenue and Market Share by Manufacturer 3.3 Market Concentration Rate 3.3.1 Top 3 Apheresis Equipment Manufacturer Market Share 3.3.2 Top 6 Apheresis Equipment Manufacturer Market Share 3.4 Market Competition Trend 4 Global Apheresis Equipment Market Analysis by Regions 4.1 Global Apheresis Equipment Sales, Revenue and Market Share by Regions 4.1.1 Global Apheresis Equipment Sales by Regions (2011-2016) 4.1.2 Global Apheresis Equipment Revenue by Regions (2011-2016) 4.2 North America Apheresis Equipment Sales and Growth (2011-2016) 4.3 Europe Apheresis Equipment Sales and Growth (2011-2016) 4.4 Asia-Pacific Apheresis Equipment Sales and Growth (2011-2016) 4.5 South America Apheresis Equipment Sales and Growth (2011-2016) For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.
News Article | February 20, 2017
According to a new market research report "Apheresis Market by Product (Plasma & Component Separator, Hemoperfusion, and Disposable), Procedure (Therapeutic, Photopheresis, and Donor), Application (Plasmapheresis, Plateletpheresis), Technology (Centrifuge, Membrane Separation) - Global Forecast to 2021" published by MarketsandMarkets, the global market is projected to reach USD 2.06 Billion by 2021, at a CAGR of 7.7% from 2016 to 2021. Browse 174 market data Tables and 47 Figures spread through 212 Pages and in-depth TOC on "Apheresis Market" Early buyers will receive 10% customization on this report. The rising incidence of chronic lifestyle diseases such as diabetes, kidney disorders, & respiratory diseases, increasing demand for blood components, and favorable reimbursement scenario are the key factors driving the growth of the market. However, scarcity of qualified donors and the high cost of apheresis machines & procedures are restraining the growth of this market. In this report, the market is majorly segmented by product, procedure, technology, application, and region. Based on product, the market is segmented into devices and disposables. The disposables segment accounted for the largest share and will be the fastest growing market during the forecast period. This is attributed to the increasing demand for disposables and rising preference for apheresis blood collection. On the basis of procedure, the market is segmented into automated/donor apheresis and therapeutic apheresis. Therapeutic apheresis is further segmented into therapeutic plasma exchange (TPE), therapeutic cytapheresis, photopheresis, and extracorporeal immunoadsorption (ECI). In 2015, therapeutic plasma exchange segment accounted for the largest share of the market. The large share of this segment is attributed to the increasing prevalence and incidence of various blood disorders such as sickle-cell anemia and leukemia. The photopheresis segment is expected to register the highest CAGR during the forecast period due to the increasing demand for photopheresis in organ transplant rejection treatment. In 2015, North America accounted for the largest share of the market, followed by Europe. The presence of established distribution channels, growing applications of apheresis products in plasma collection and fractionation, and rising number of hemophilic patients are driving the growth of the North American apheresis market. The Asia-Pacific region is expected to witness the highest growth in this market majorly due to improving healthcare infrastructure and growing economies in China and India. In addition, manufacturers are increasingly focusing on strengthening their presence in emerging APAC countries. The global Apheresis Market is highly competitive in nature, with the top five companies accounting for the major market share in 2015. Some of the key players in this market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), Cerus Corporation (U.S.), B. Braun Melsungen AG (Germany), HemaCare Corporation (U.S.), Kaneka Corporation (Japan), and Nikkiso Co., Ltd. (Japan). These leading players primarily focused on product launches, acquisitions, agreements, collaborations, partnerships, and expansions to help growth in the market. U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain-Barré Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021 MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
News Article | December 15, 2016
DENVER--(BUSINESS WIRE)--Colorado’s life science sector wraps up a year marked by an expanded presence for a global biologics manufacturer, notable regulatory successes for companies developing breakthrough biologics, drugs and medical devices, significant partnerships created to draw on the state’s collaborative spirit and commitment to innovation and notable grant-making and fundraising activities. New numbers from Colorado’s Office of Economic Development and International Trade (OEDIT) show the long-term impact of investment in bioscience. In 2016, OEDIT provided $8.68 Million to Colorado bioscience companies through the Advanced Industries (AI) Grant Program. Since inception, this industry-critical program supporting the bioscience sector in Colorado has awarded $45.9 Million in grants, and continues to make an economic impact in the state, creating: April Giles, President and CEO of Colorado BioScience Association says: “From the long-term success of the AI grant program, to innovative start-ups achieving critical financing and regulatory goals, to a major global manufacturer choosing Colorado for continued expansion, our state’s life science industry will look back on 2016 as milestone year. Colorado is recognized as an epicenter for big ideas and major breakthroughs, with a collaborative and supportive community of people committed to improving human health and quality of life.” Many Colorado bioscience organizations met significant business and regulatory milestones, raised funds and received grants. Notable examples of the 2016 successes achieved by CBSA members include: Colorado companies raised hundreds of millions of dollars to invest in research and development and support commercialization. Examples include: Innovators at all stages of development received grants, donations and awards from individuals, government entities and industry organizations. Access to these sources of non-dilutive funding is critical to support research and continued industry growth. AstraZeneca, a global biologics manufacturer expanded its Colorado presence through the acquisition of a second Colorado site. The company purchased the former Amgen, Inc. biologics manufacturing property in Longmont to support operations at its Boulder site, acquired in 2015. Colorado companies received at least ten FDA approvals or clearances on biologics, medical devices and drugs. Additionally, the FDA accepted several New Drug Applications (NDAs) and granted one Investigational Device Exemption (IDE) to companies based in our state. Additionally, at least five companies were granted U.S. patents or European CE marks. Four Colorado companies announced mergers and acquisitions in 2016. miRagen and Signal Genetics, Inc. (Nasdaq: SGNL) entered into a definitive merger agreement to form miRagen Therapeutics, Inc., allowing miRagen to become a public company, trading under the Nasdaq ticker symbol MGEN when the transaction becomes final. Additionally, Schryver Medical Sales and Marketing, LLC acquired Professional Clinical Laboratory, Inc. (“ProLab”) to bolster its presence in the Texas market; Venaxis Inc. (Nasdaq: APPY) acquired Boulder-based BiOptix Diagnostics, Inc.; and Sartorius acquired ViroCyt to expand the lab products and services offered by Sartorius. Colorado’s reputation as an epicenter for big ideas and a collaborative culture attracted new centers focused on innovation and partnerships created to tackle major healthcare challenges. Catalyst HTI – The industry integrator focused on health tech innovation, scheduled to open in early 2018, announced several anchor tenants, including University of Colorado Anschutz, Terumo BCT, American Diabetes Association and Hitachi Consulting. StartUp Health – Launched its Rocky Mountain innovation hub, StartUp Health Colorado in partnership with Children’s Hospital Colorado, University of Colorado Anschutz and UCHealth to support healthcare entrepreneurs from around the world. Catholic Health Initiatives and Dignity Health – Created the Precision Medicine Alliance to offer patients of both healthcare systems faster and more accurate diagnostic and treatment protocols based on their genetic and molecular profile information. PharmaJet – Announced a multi-year partnership as part of the World Health Organization’s focus on eradicating polio, using the Colorado company’s Tropis device to administer medication through the skin without needles. Colorado’s almost 725 life science organizations range from those moving from early-stage research and development, through clinical trials and into full-fledged commercialization. Those companies are responsible for close to 600 commercial products developed in Colorado. Colorado BioScience Association champions life science. We serve as the hub of Colorado’s thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. From promising young companies to established corporations and institutions, we provide opportunities for networking, education and professional development. We grow the bioscience workforce and lead business expansion policies to advance the industry in our state. CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers. Learn more about us at http://www.cobioscience.com.
News Article | October 28, 2016
Terumo BCT will exhibit apheresis collection and blood processing technologies at the annual AABB 2016 Meeting, a premier event targeting blood center and hospital professionals interested in advancing transfusion and cell therapy. As a key meeting sponsor and global leader in this area, Terumo BCT will participate in CME sessions, host a symposium and demonstrate its technologies at AABB 2016. Innovations on display in the booth #937 include: Trima Accel® Automated Blood Collection System–The world’s leading apheresis collection device and the only system on the market today that can collect any transfusable component, in any combination, helping blood centers better meet the demand for blood in their communities. The device can be used for in-center collections or on mobile drives and is supported by a range of innovative business intelligence and operational software that helps drive efficiencies and quality. Spectra Optia® Apheresis System–The industry's next-generation therapeutic apheresis and cell collection platform designed to help operators spend more time focusing on patient care. Terumo BCT Suite of Software Solutions–Innovative technologies that help customers harness the power of connectivity and real-time data, providing visibility into a blood center’s collection and processing procedures. Terumo BCT is an exclusive authorized distributor of B Medical Systems biomedical refrigeration products in the United States and Canada. Please visit B Medical Systems at booth #1044 for product demonstrations. Other Terumo BCT activities taking place throughout the course of the meeting are as follows: 1:00 p.m. Room W230 A/B Orange County Convention Center Pre-Conference Workshop: (HEMO) Hemovigilance Workshop: Learn How Hemovigilance is Practiced in the U.S. and How Hospitals Can Participate Palani Palaniappan, Executive Vice President,Innovation & Development - Terumo BCT “Safety Innovations and Hemovigilance: Broad Perspectives on Enabling Technologies” 7:00 a.m. Room W240 Orange County Convention Center Breakfast Symposium: Bringing Value to Your Blood Center: The Potential of Apheresis Therapies Richard Smith, Global Clinical Scientist, Terumo BCT "Apheresis Optimization for Immunotherapy Collections” Ross Fasano, MD Assistant Professor, Pathology & Laboratory Medicine, Emory University School of Medicine “Value of Red Blood Cell Exchange for Sickle Cell Disease Patients and the Impact to Blood Centers” About Terumo BCT Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
News Article | September 5, 2016
Companies that sell devices to screen or treat blood stand to benefit from a new FDA recommendation that the entire blood supply in the U.S. and its territories be tested for the Zika virus. Previously, the agency had advised testing of blood donations only in areas such as Florida and Puerto Rico with active virus transmission. Now it says 11 states close to these areas or having other Zika risk factors should start testing within four weeks. All other states have 12 weeks. The added safety precautions have been put in place because “there is still much uncertainty regarding the nature and extent of Zika virus transmission,” according to Peter Marks, director of FDA’s Center for Biologics Evaluation & Research. To handle the task, FDA has granted emergency use authorizations to companies developing as-yet-unapproved methods to test donated whole blood and blood components for Zika. Eight authorizations have been awarded since April, with the most recent going to Roche last week for its PCR-based test. As an alternative to testing, blood centers can use an FDA-approved pathogen reduction device. In 2014, FDA approved Cerus’s Intercept Blood System for plasma and platelets. The company’s technology uses compounds that intercalate into viral DNA and irreversibly cross-link to inactivate viruses. A system for red blood cells is in Phase III clinical testing in Europe. With 15 U.S. blood centers using its technology routinely and 30 under contract, Cerus serves 80–85% of the market, CEO William Greenman says. “We are pursuing the deployment of the red blood cell system under an investigational device exemption,” he adds. In June, the federal Biomedical Advanced Research & Development Authority (BARDA) agreed to pay $31 million over three years to support Cerus’s near-term clinical trials. Of that, $11 million will go toward evaluating the Intercept red blood cell system in Puerto Rico. BARDA is also spending $18 million to help Terumo BCT develop its Mirasol system for treating platelets. If extended, each contract is worth more than $150 million. Testing and pathogen reduction are designed to increase the safety of the blood supply, but they are unlikely to provide information on transmission. Only about 2% of the U.S. population donates blood annually, according to the National School of Tropical Medicine at Baylor College of Medicine.
News Article | October 28, 2016
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that Antoinette Gawin has been appointed Executive Vice President, Global Commercial and a key member of the Terumo BCT Executive Management Committee. In this role, Gawin is responsible for global sales, marketing, business development and all commercial operations, as well as establishing the Company’s go-forward strategy and the associated infrastructure required to expand its position in emerging markets. Gawin brings a wealth of knowledge and experience in sales leadership, strategic marketing and business development with nearly 30 years working in Fortune 100 companies, directing diverse global teams and transforming organizations. Gawin served in several leadership roles at Baxter Healthcare, overseeing global market access, strategy and commercial operations. During her tenure, she restructured and accelerated growth for the commercial organization within the $5-billion Medication Delivery business. She successfully architected a company-wide cultural transformation, increasing profits and employee satisfaction during the first year. Gawin also built an organization of health economists and market access experts to influence global reimbursement coverage and catalyze physician and patient advocacy. For 22 years, Gawin served in senior positions at GE Healthcare Technologies, GE Industrial and Power Systems, GE Information Systems and GE Corporate. Responsible for several business units, she was most recognized for her ability to work cross-functionally and successfully lead and influence large matrixed and virtual teams to higher performance. Along with residing in Scotland and Switzerland, Gawin has an extensive global background. This includes leading such diverse teams as strategic marketing, business development, information systems and finance, positioning her to drive international growth for each subsidiary. Gawin is a recognized key opinion leader in the U.S. healthcare industry and is a frequently sought-after keynote speaker on such crucial topics as the Affordable Care Act, healthcare economics, customer intimacy programs and the future of innovation in healthcare. “The depth and breadth of Antoinette’s leadership and global healthcare expertise will be immensely beneficial not only to our company but also to our customers and our overall industry,” said David Perez, President and CEO, Terumo BCT. “Her commercial strategy, business development and health policy background will guide Terumo BCT in navigating our future in the evolving global healthcare marketplace, and her steadfast passion for the customer and the patient make her an ideal cultural fit for our organization.” About Terumo BCT Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
News Article | December 22, 2016
Sarasota, FL, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Cell Separation Technologies Market by Technology (Gradient Centrifugation and Separation Based on Surface Markers) for Stem Cell Research, Immunology, Neuroscience and Cancer Research: Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global cell separation technologies market was valued at around USD 2.23 billion in 2015 and is expected to reach approximately USD 3.82 billion by 2021, growing at a CAGR of around 9.5% between 2016 and 2021. Cell separation is an essential tool, which is broadly used in many strands of biomedical and biological research and in clinical therapy. Cell separation tool are used to separate specific cells from the heterogeneous cell mixture. Cell separation reagent allows the isolation of any cell from any species. Browse through 27 Market Tables and 17 Figures spread over 110 Pages and in-depth TOC on “Global Cell Separation Technologies Market: Type, Technology, Application, Size, Share, Analysis, Segment and Forecast 2015-2021”. The cell separation technologies market is expected to witness significant growth in the years to come. The market is mainly driven by growing aging population coupled with increasing incidences of chronic diseases such as cancer. Furthermore, increasing government support and strong growth in research & development activities targeting cell therapies is anticipated to fuel the cell separation technologies market growth in the coming years. However, the high cost of cell separation tools is expected to pose a threat to the market growth within the forecast period. Nonetheless, the noteworthy technological advancements over the decade and their adoption in the healthcare sector are expected to act as new growth opportunity during the forecast period. Based on technology, cell separation market can be segmented into technology such as separation based on surface markers and gradient centrifugation. Separation based on surface marker technology is also bifurcated into Fluorescence Activated Cell Sorting (FACS) and Magnetic Activated Cell Sorting (MACS). In 2015, magnetic activated cell sorting was the leading segment due to the accuracy level and faster results provided. Browse the full "Cell Separation Technologies Market by Technology (Gradient Centrifugation and Separation Based on Surface Markers) for Stem Cell Research, Immunology, Neuroscience and Cancer Research: Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/cell-separation-technologies-market Some of the key technologies such as gradient centrifugation techniques and FACS, chromatography sieving, panning, and lab on a chip are currently under development. The global cell separation technologies market is segmented on the basis of application such as immunology, stem cell research, cancer research and neuroscience research. The stem cell research segment accounted for the largest share in 2015. Rising demand for cell therapies and higher potential of stem cells have increased research and development activities within the stem cell research segment. Cancer research was another leading segment and is expected to propel the market growth in the years to come. This growth is mainly due increasing incidences of cancer and other cell-based diseases worldwide. In terms of revenue, North America accounted for largest share of the global cell separation technologies market and is set to dominate the world marketplace within the forecast period. This growth is mainly due to the increasing demand for treatment from the aging population. Moreover, increasing investments in the healthcare industry and growing R&D initiatives is further expected to boost the market growth in the near future in this region. North America cell separation technologies market was led by the U.S. as a result of increasing technological advancement in this region. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/cell-separation-technologies-market In terms of revenue, North America closely followed by Europe in 2015. Europe is expected to exhibit witness significant growth in the years to come. The growth is mainly due to increase concern regarding health among people. Moreover, technological advancement and improvement in health care infrastructure expected to boost the market growth in the years to come. Asia Pacific cell separation technologies market is projected to be the fastest growing regional market within the forecast period. Furthermore, cell separation technologies market has the huge opportunity in the emerging markets of Asia Pacific due to the escalating aging population, increasing health awareness about cell separation technologies treatment and increasing investment in the healthcare sector especially in China and India. The Middle East & Africa is expected to experience significant growth in the years to come. This growth is attributed to the increasing healthcare awareness coupled with advancement in technology. Latin America is another key regional market and is expected to experience significant growth over the forecast period. The growth is mainly due to the increasing demand for cell separation technologies treatment coupled with technological advancement. Thus, all aforementioned parameters are expected to drive the market growth in this region. Some of the key players in cell separation technologies market include EMD Millipore, Mitenyi Biotec GmbH, BD Bioscience, and STEMCELL Technologies, Terumo BCT, pluriSelect GmbH, and Thermo Fisher Scientific, Inc. This report segments the global cell separation technologies market as follows: Global Cell Separation Technologies Market: Technology Segment Analysis Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.